Tests JNJ-90301900 added to chemoradiation for lung cancer
Tests JNJ-90301900 with chemoradiation and durvalumab in adults with locally advanced lung cancer.
Plain-language title generated from the registry record
Registry title: A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Key facts
- Where
- Amsterdam and Nijmegen, NetherlandsSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer that cannot be removed by surgery and who can have chemotherapy with radiation followed by durvalumab.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced, unresectable stage III non-small cell lung cancer, proven by tissue or cell tests within 3 months before joining. At least 1 target tumour or lymph node that can be injected and treated with radiation.
- Earlier treatment
- Must be a candidate for chemotherapy (platinum-based) with radiation, followed by durvalumab. No other earlier treatment is named in the record.
Main reasons for not taking part
- Primary immunodeficiency
- Organ transplant that needs treatment to lower the immune system
- Severe heart problems within 3 months, such as heart attack, unstable angina or heart failure class III to IV
- Another cancer within the last 36 months
- Bleeding or clotting problems, or a major blood clot event within 3 months
Read by machine on 9 November 2026.
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johnson & Johnson Enterprise Innovation Inc.
- Trial code
- NCT06667908EU 2024-518276-32-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.Read full original descriptionShow less
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Inclusion: Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening; Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization; Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification; Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening; Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1.
Exclusion: Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV; Another concurrent or prior primary malignancy within the last 36 months at informed consent; Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression; Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab; History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization.